Lilly Cautions On Zyprexa Use For Dementia-Related Psychosis In Elderly
This article was originally published in The Pink Sheet Daily
Executive Summary
"Dear Doctor" letter calls attention to clinical trial data showing increased incidence of mortality and cerebrovascular events compared to placebo. Lilly has discontinued studying Zyprexa in elderly patients with dementia.
You may also be interested in...
Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia
FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.
Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia
FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.
Abilify Adds Bipolar Maintenance Claim And Cerebrovascular Warning
Bristol-Myers Squibb/Otsuka's atypical antipsychotic becomes second drug in class, after Lilly's Zyprexa, with bipolar maintenance indication. Abilify also joins Zyprexa and J&J's Risperdal with warning on cerebrovascular adverse events in elderly dementia patients.